Treatment with rituximab in benign and malignant hematologic disorders in children.
about
Rituximab for treating inhibitors in people with inherited severe hemophiliaRituximab for treating inhibitors in children with hemophiliaUse of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)Childhood immune thrombocytopenia: Clinical presentation and managementRituximab in the treatment of autoimmune haematological disorders.Autoimmune manifestations in common variable immunodeficiency.Idiopathic thrombocytopenic purpura in childhood: a 10-year audit.Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.Immunomodulation for inhibitors in hemophilia A: the important role of Treg cellsRituximab in steroid refractory autoimmune hemolytic anemia.Rituximab for treating inhibitors in people with inherited severe hemophilia.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.Construction and expression of single-chain antibody derived from a new clone of monoclonal antibody against human CD14 in CHO cells.Association of autoimmune hepatitis type 1 in a child with Evans syndrome.Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE.A clinicopathologic case study of two patients with pediatric orbital IgG4-related disease.Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders.Successful treatment with rituximab of an infant with refractory autoimmune hemolytic anemia.
P2860
Q24186623-52529F7B-1737-41C0-ADA3-DFFB0DE008C6Q24197700-DA5E9EC6-ADB2-4B1A-AA13-F7E0D560AB72Q24643047-51243F65-6F1E-45C7-AA17-F07A9CB83C91Q27023294-AF1637F0-7753-4A64-B9DC-2E3530E5E34BQ33378854-77031B2E-DB53-45DE-9E92-DC300F2AD1E1Q33378880-DF013E20-7FB2-4AE9-A5B7-E8EE0158D8F7Q33380751-47AA428C-5572-4EFD-B1D5-335EB3975A69Q33389561-5547D996-6CF0-4D0D-80DE-ECD5D3634806Q37803130-6260DB21-D179-424E-8B4F-5F9B0D52E948Q37914758-39045D20-CB2D-46D0-A6A5-92B48952750DQ38661525-7E942A02-D90F-4DF2-AACD-4361F06B2EDBQ39279968-90C3C882-14EE-4E53-B1D9-C79A090F738FQ40036380-C6BDABD6-2CBF-45D9-8DE3-A0E489DAFE4AQ41505520-64935EDC-0287-459A-A3B9-81EE5C074B4AQ46076323-724DCA17-4E63-445D-B5F5-908CBA5A3ADBQ47748689-0459E3A7-4427-4DCE-810B-7C08D36974C4Q47973396-EE53D6B9-04E1-4535-9469-8B31919F721BQ50965179-A874ED21-33E1-4473-BA96-E8B5EC7C9EBE
P2860
Treatment with rituximab in benign and malignant hematologic disorders in children.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Treatment with rituximab in benign and malignant hematologic disorders in children.
@ast
Treatment with rituximab in benign and malignant hematologic disorders in children.
@en
type
label
Treatment with rituximab in benign and malignant hematologic disorders in children.
@ast
Treatment with rituximab in benign and malignant hematologic disorders in children.
@en
prefLabel
Treatment with rituximab in benign and malignant hematologic disorders in children.
@ast
Treatment with rituximab in benign and malignant hematologic disorders in children.
@en
P2860
P1476
Treatment with rituximab in benign and malignant hematologic disorders in children.
@en
P2093
Lisa B Giulino
Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network
P2860
P304
338-44, 344.e1
P356
10.1016/J.JPEDS.2006.12.038
P407
P577
2007-04-01T00:00:00Z